Search

Your search keyword '"Arsene Mekinian"' showing total 77 results

Search Constraints

Start Over You searched for: Author "Arsene Mekinian" Remove constraint Author: "Arsene Mekinian"
77 results on '"Arsene Mekinian"'

Search Results

1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

2. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trialsResearch in context

3. Patterns of patient-reported symptoms and association with sociodemographic and systemic sclerosis disease characteristics: a scleroderma Patient-centered Intervention Network (SPIN) Cohort cross-sectional studyResearch in context

4. Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients

5. Systemic sclerosis associated interstitial lung disease: a survey of current practices in France

6. CovAID: Identification of factors associated with severe COVID-19 in patients with inflammatory rheumatism or autoimmune diseases

7. Endometriosis and autoimmunity

8. Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial

9. Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis

11. Clinical spectrum and outcome of Takayasu’s arteritis in children

12. Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group

13. Pleuropulmonary Manifestations of Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic (VEXAS) Syndrome

14. Syndrome VEXAS

15. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML

16. Use of platelet inhibitors for digital ulcers related to systemic sclerosis: EUSTAR study on derivation and validation of the DU-VASC model

17. A qualitative interview study exploring the psychological health impacts of the SPIN-CHAT program among people with systemic sclerosis at the onset of COVID-19: Perceptions of trial participants and research team members

18. The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial

19. Corrigendum to 'Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group' [Placenta. 136 (2023 Apr 3) 29–34]

20. Very long-term remission with azacitidine in VEXAS syndrome

21. Vasodilator drugs and heart-related outcomes in systemic sclerosis: an exploratory analysis

22. Higher risk profile among patients with TET2-mutated giant cell arteritis: a cluster analysis

23. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

24. Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: A multicentre cross-sectional study

25. Factors associated with fears due to COVID-19: A Scleroderma Patient-centered Intervention Network (SPIN) COVID-19 cohort study

26. Regulatory B Cell Imbalance Correlates With TFH Expansion in Systemic Sclerosis

27. Drug-induced antiphospholipid syndrome: Analysis of the WHO international database

28. Prevalence and association of placental lesions with obstetrical features and outcome: data from French prospective studyAJOG Global Reports at a Glance

29. Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease

30. Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database

31. Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients

32. Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1–phase 2a study

33. Ophthalmic vascular manifestations in eosinophil-associated diseases: a comprehensive analysis of 57 patients from the CEREO and EESG networks and a literature review

34. Thoracic aorta involvement in giant cell arteritis: a case-control analysis of morphological data at diagnosis

35. Factors associated with satisfaction with social roles and activities among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort cross-sectional study

36. History of pre-eclampsia does not appear to be a risk factor for vascular phenotype in women with systemic sclerosis

37. Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort

38. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation

42. Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial

43. Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study

44. Identifying high-risk profile in primary antiphospholipid syndrome through cluster analysis: French multicentric cohort study

45. Triple positive profile in antiphospholipid syndrome: prognosis, relapse and management from a retrospective multicentre study

46. Non-criteria manifestations in primary antiphospholipid syndrome: a French multicenter retrospective cohort study

47. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study

48. Construction of Cohorts of Similar Patients From Automatic Extraction of Medical Concepts: Phenotype Extraction Study

49. Rituximab in central nervous system manifestations of patients with primary Sjögren's syndrome: results from the AIR registry

50. Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment

Catalog

Books, media, physical & digital resources